VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 122 filers reported holding VERVE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $420,925 | -27.2% | 31,744 | +2.9% | 0.00% | -42.9% |
| Q2 2023 | $578,306 | +100650.2% | 30,843 | -22.5% | 0.01% | -22.2% |
| Q1 2023 | $574 | +12.8% | 39,774 | +51.3% | 0.01% | -10.0% |
| Q4 2022 | $509 | -99.9% | 26,285 | +8.5% | 0.01% | -23.1% |
| Q1 2022 | $553,000 | +16.2% | 24,216 | +206.4% | 0.01% | +44.4% |
| Q2 2021 | $476,000 | – | 7,904 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |